Zydus Lifesciences rises on getting USFDA’s final approval for Ibuprofen and Famotidine Tablets
Zydus Lifesciences is currently trading at Rs. 895.00, up by 9.90 points or 1.12% from its previous closing of Rs. 885.10 on the BSE.
The scrip opened at Rs. 886.40 and has touched a high and low of Rs. 897.50 and Rs. 881.95 respectively. So far 3834 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 862.20 on 19-Feb-2025.
Last one week high and low of the scrip stood at Rs. 928.95 and Rs. 862.20 respectively. The current market cap of the company is Rs. 89751.04 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.18% and 6.84% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Ibuprofen and Famotidine tablets, 800 mg/26.6 mg. (USRLD: Duexis Tablets, 800 mg/26.6 mg).
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers (gastric and/or duodenal ulcers), in patients who are taking ibuprofen for those indications. Ibuprofen and famotidine tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad.
Ibuprofen and Famotidine tablets had annual sales of $3.6 million in the United States (IQVIA MAT December 2024). The group now has 415 approvals and has so far filed 483 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
